FLT1 and cancer: In the present study, we evaluated the immunohistochemical expression of VEGF-A, VEGF-C, VEGFR1, VEGFR2 and VEGFR3 in tumor tissue sections of early-stage breast cancer patients who had participated in a randomized adjuvant chemo-hormonotherapy trial of the Hellenic Cooperative Oncology Group (HeCOG)[24] and correlated it with clinicopathological parameters, cancer subtypes and survival outcome.